160376-79-4

Upstream product

• 170291-52-8 tert-butyl 4-(4-fluorophenyl)-4-(hydroxymethyl)piperidine-1-carboxylate 
• 644981-89-5 1-(tert-butoxycarbonyl)-4-(4-fluorophenyl)piperidine-4-carboxylic acid 
• 1429661-32-4 C₁₉H₂₆FNO₄ 
• 672927-13-8 4-(4-fluorophenyl)-1-methyl-4-piperidinecarboxylic acid hydrochloride 

Downstream Products

• 1421961-56-9 4-(((6-cyclopropyl-4-(trifluoromethyl)pyridine-2-yl)methoxy)methyl)-4-(4-fluorophenyl)-1-methylpiperidin-1-ium chloride 
• 672927-11-6 1-N-methyl-4-(4-fluorophenyl)-4-((3-cyanonaphth-1-yl)methoxymethyl)piperidine 

Relevant academic research and scientific papers

Development of a scalable route to a dual NK-1/serotonin receptor antagonist

The evolution of a process for the preparation of a new heterocyclic dual NK1/serotonin receptor antagonist is described. The final synthesis features a telescoped sequence in which an iron(III)-catalyzed Grignard coupling is followed by a benzylic chlori

NAPHTHYL ETHER COMPOUNDS AND THEIR USE

Compounds having the following structure wherein R1, R2, R3, R4, R5, R6, R7 m and n are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically-acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same.